Skip to content

Eli Lilly LLY Other intangible assets—net

Other intangible assets—net at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$49.06B+33.5%
Cencora logo
CencoraCOR
$6.05B+56.7%
Pfizer logo
PfizerPFE
Amgen logo
AmgenAMGN
Cardinal Health logo
Cardinal HealthCAH
Biogen logo
BiogenBIIB

Other financials

Income statement

See full
Revenue$19.8B+55.5%
Gross profit$16.2B+54.4%
Net income$7.4B+168%
EPS (diluted)$8.26+170%

Balance sheet

See full
Cash & equivalents$5.3B+70.8%
Total debt$43.4B+12.6%
Total equity$31.2B+97.9%
Total assets$116.58B+30.4%

Cash flow

See full
Operating cash flow$5.3B+220%
CapEx$2.3B+54.0%
Free cash flow$3.0B+1,828%

Valuation

See full
Market cap$979.64B+10.8%
Enterprise value$1.02T+10.6%
P/E38.8×-40.9×
P/S13.6×-4.5×

Profitability

See full
Gross margin82.8%+1.1pp
Net margin35%+12.3pp
FCF margin16.4%+8.7pp

Returns & leverage

See full
Return on equity107.6%+29.9pp
Debt / equity1.4×-1.1×
Current ratio1.5×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.

The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eli Lilly's other intangible assets—net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eli Lilly's other intangible assets—net?
Eli Lilly (LLY) reported other intangible assets—net of $7.37B in Q1 2026.
How has Eli Lilly's other intangible assets—net changed year-over-year?
Eli Lilly's other intangible assets—net increased by 22.7% year-over-year, from $6.01B to $7.37B.
What is the long-term trend for Eli Lilly's other intangible assets—net?
Over 5 years (2020 to 2025), Eli Lilly's other intangible assets—net has grown at a -2.6% compound annual growth rate (CAGR), from $7.45B to $6.52B.